Natixis Advisors LLC Buys 4,498 Shares of Axon Enterprise, Inc $AXON

Natixis Advisors LLC raised its stake in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 18.8% in the third quarter, Holdings Channel reports. The institutional investor owned 28,375 shares of the biotechnology company’s stock after buying an additional 4,498 shares during the quarter. Natixis Advisors LLC’s holdings in Axon Enterprise were worth $20,363,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. increased its holdings in shares of Axon Enterprise by 2.8% during the second quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company’s stock valued at $421,000 after acquiring an additional 14 shares in the last quarter. Vicus Capital raised its holdings in Axon Enterprise by 3.7% in the third quarter. Vicus Capital now owns 396 shares of the biotechnology company’s stock worth $284,000 after buying an additional 14 shares during the last quarter. Evergreen Capital Management LLC grew its holdings in shares of Axon Enterprise by 3.8% during the second quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 15 shares during the last quarter. Blue Trust Inc. increased its position in shares of Axon Enterprise by 2.5% during the third quarter. Blue Trust Inc. now owns 645 shares of the biotechnology company’s stock valued at $463,000 after acquiring an additional 16 shares in the last quarter. Finally, NorthCrest Asset Manangement LLC raised its holdings in Axon Enterprise by 5.4% in the 3rd quarter. NorthCrest Asset Manangement LLC now owns 313 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 16 shares during the last quarter. 79.08% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Axon Enterprise news, insider Isaiah Fields sold 2,000 shares of the business’s stock in a transaction dated Friday, February 27th. The stock was sold at an average price of $535.01, for a total transaction of $1,070,020.00. Following the completion of the sale, the insider directly owned 55,588 shares in the company, valued at $29,740,135.88. The trade was a 3.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Jennifer H. Mak sold 1,500 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $573.45, for a total transaction of $860,175.00. Following the sale, the chief accounting officer directly owned 12,240 shares of the company’s stock, valued at $7,019,028. The trade was a 10.92% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 24,634 shares of company stock valued at $13,803,095. Insiders own 4.40% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Northcoast Research raised Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective on the stock in a research report on Tuesday, January 6th. Royal Bank Of Canada decreased their price target on Axon Enterprise from $860.00 to $735.00 and set an “outperform” rating for the company in a research note on Wednesday, February 25th. Wall Street Zen raised Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research report on Monday, December 29th. Finally, Robert W. Baird set a $800.00 price objective on Axon Enterprise in a report on Wednesday, February 25th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $762.93.

Axon Enterprise Price Performance

Shares of AXON opened at $517.57 on Thursday. The firm has a fifty day simple moving average of $533.80 and a two-hundred day simple moving average of $613.08. The firm has a market cap of $41.61 billion, a PE ratio of 340.51, a P/E/G ratio of 11.31 and a beta of 1.46. The company has a current ratio of 2.53, a quick ratio of 2.29 and a debt-to-equity ratio of 0.53. Axon Enterprise, Inc has a 1-year low of $396.41 and a 1-year high of $885.91.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $2.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.55. The firm had revenue of $796.72 million for the quarter, compared to the consensus estimate of $755.29 million. Axon Enterprise had a return on equity of 2.82% and a net margin of 4.48%.The company’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same period last year, the business posted $2.08 EPS. On average, equities analysts anticipate that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Axon Enterprise News Summary

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Recent operating momentum and scale: company commentary and filings highlighted robust device and software demand, rising ARR/bookings and accelerating revenue that underpinned the prior rally. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Analyst backing and price-target runway: multiple firms maintain buy/overweight ratings and the median 6‑month target sits well above current levels, giving upside for longer-term holders. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Positive Sentiment: Momentum recap: AXON had climbed nearly 29% over the prior month on strong device/software demand — a factor that supports the bull case if execution continues. Axon Stock Rises 28.6% in a Month: Should Investors Buy or Wait?
• Neutral Sentiment: No meaningful short-interest signal (data shows zero or NaN) — likely a reporting anomaly, so it shouldn’t be interpreted as a fresh bearish catalyst.
• Neutral Sentiment: Third‑party/industry headlines referencing “Axon” (e.g., AppLovin’s “Axon by AppLovin” product and related studies) are unrelated to Axon Enterprise’s business and can confuse coverage — treat those items as industry noise. AppLovin (APP) Is Up 19.5% After Showcasing AXON 2.0 And AI E-commerce Pivot
• Negative Sentiment: Profit‑taking and valuation sensitivity: analysts and market commentary point to a classic post‑earnings retracement after a fast run; high valuation metrics make the stock susceptible to short‑term pullbacks. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Heavy insider selling noted in recent disclosures increases near‑term perceived risk and can sap sentiment even if proceeds are routine. Axon slips as investors digest rich valuation after a sharp post-earnings run-up
• Negative Sentiment: Relative underperformance vs. peers on the day added selling pressure, suggesting short‑term rotation rather than a fresh fundamental shift. Axon Enterprise Inc. stock underperforms Tuesday when compared to competitors

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.